The pulmonary route as a way to drug repositioning in COVID-19 therapy.

ABSTRACT:

Introduction

The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery.

Objective

Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration.

Method

A integrative literat

SUBMITTER: Sarcinelli MA 

PROVIDER: S-EPMC7903910 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature